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Anaphylactic Shock
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and John Wilson
Abstract
Anaphylaxis is a life threatening hypersensitivity reaction that can cause shock. 
Epidemiology studies show anaphylaxis and anaphylactic shock is relatively rare, 
but its incidence is increasing. A review of the pathophysiology of anaphylaxis can 
provide insight into clinical decisions. Diagnosing anaphylaxis can be difficult as 
symptoms and history are not always obvious. Diagnostic guidelines provide an 
objective tool to assess for anaphylaxis. Early intervention during anaphylaxis may 
prevent development of shock. Management is focused on circulation support with 
epinephrine and IV fluids, and airway maintenance. Following an acute anaphylac-
tic reaction, patients should be provided with a referral for follow up and educated 
on avoidance of triggers and use of epinephrine autoinjectors.
Keywords: anaphylaxis, anaphylactic shock, distributive shock, management
1. Introduction
In this chapter, we will learn the differences between anaphylaxis and anaphylac-
tic shock. Epidemiology of anaphylactic shock will be reviewed. We will also discuss 
the biochemical markers and mediators most noted to triggering an anaphylactic 
reaction. Lastly, we will provide a review on clinical manifestations and management 
of an anaphylactic reaction in a nonclinical setting and in a clinical setting.
Throughout this chapter anaphylaxis will be defined according to the World 
Allergy Organization (WAO) definition ‘a severe, life-threatening generalized or systemic 
hypersensitivity reaction’ [1]. This includes Gell-Combs Type I hypersensitivity, as well 
anaphylactoid reactions that are immunologically and nonimmunological mediated.
There are few studies on anaphylactic shock, and most recommendations for 
anaphylactic shock management come from major allergy organizations: WAO, 
AAAA/ACAAI, and EAACI. The recommendations of these groups for management 
of anaphylactic shock are presented in this chapter. Recent changes in anaphylaxis 
definitions require a review of the immunologic and nonimmunologic biochemical 
pathways of anaphylaxis.
1.1 Definitions
1.1.1 Anaphylactoid reactions
Reactions that occur via mechanisms other than IgE mediated mast cell degranula-
tion have been referred to as Anaphylactoid reactions. However, the WAO, AAAA/
ACAAI, and EAACI have recommended stoppage of the term [2]. Throughout this 
chapter reactions that would be included in this term will be referred to as anaphylaxis.
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1.1.2 Anaphylaxis
Anaphylaxis is typically taught as Gell-Combs classification type 1 hypersen-
sitivity, that is IgE mediated. However, the World Allergy Organization (WAO) 
proposed a new expanded definition of anaphylaxis ‘a severe, life-threatening general-
ized or systemic hypersensitivity reaction’ [3]. This new definition of anaphylaxis now 
includes reactions previously categorized as ‘anaphylactoid reactions’.
1.1.3 Anaphylactic shock
End manifestation of anaphylaxis, occurs when there is inadequate tissue 
 perfusion causing end organ damage.
2. Epidemiology
Studies have estimated that the incidence of anaphylaxis is between 0.05 and 
2.0% of the population [4], although the actual incidence is not clear. Issues previ-
ously identified with epidemiologic studies include variations in definitions, under 
reporting of anaphylaxis, and unclear use of incidence and prevalence of disease [5].
Although the actual incidence is not clear, there have been multiple studies showing 
that the incidence of anaphylaxis in the United States has increased in recent years [6–9], 
although the case fatality rate has decreased [8]. Similar findings are reported in other 
countries, with UK reporting increasing rates of anaphylaxis [10–12], but no increase 
in the incidence of fatal anaphylaxis [10]. In Australia the incidence of anaphylaxis 
[13–15] and fatal anaphylaxis has increased as well [16]. One study on the incidence of 
anaphylaxis with circulatory symptoms found a rate of approximately 8–9 cases per 
100,000 persons per year [17]. Severe anaphylaxis, including respiratory or circulatory 
symptoms, occurs more frequently at a rate of about 1–3 per 10,000 people [18].
Factors that may affect the incidence of anaphylaxis include geography, seasonal 
variations, age, and gender [19]. Demographic factors associated with higher 
incidence include living in northern areas of US [7, 20].
3. Pathophysiology
Anaphylaxis is caused by massive release of biochemical mediators from mast 
cell and basophils. Mast cells activation occurs mainly via antigen crosslinking of 
IgE bound to FcεRI receptors on cell membranes. However, other membrane recep-
tors can activate mast cells as well or potentiate IgE activation [21]. The multiple 
activation pathways allow for immunologic (e.g. IgE mediated) and/or nonimmu-
nologic activation (e.g. drug directly interacting with receptors) (Figure 1: mecha-
nisms of mast cell degranulation). Some antigens may mediate effects via several 
mechanisms simultaneously (e.g. vespid venom, NSAIDs, opiates). In non-IgE 
mediated anaphylaxis, symptoms can occur on first exposure to an antigen as prior 
exposure and sensitization is not required.
Reproduced from Spoerl et al. [22] in agreement with publishing under terms of 
the Creative Commons Attribution (CC BY) license.
3.1 Triggers and cell activation
In IgE mediated anaphylaxis, an immunogen cross links membrane bound IgE 
in previously sensitized mast cell. Immunogens are typically large foreign proteins 
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with multiple epitope binding sites (e.g. proteins in insect venom and certain foods) 
[23]. Antigens that are too small to cross link IgE (e.g. penicillin) must first bind to 
larger carrier molecules in order to elicit an immune response. Common triggers of 
IgE-mediated anaphylaxis include various food, venom and medications are sum-
marized in Table 1: IgE-dependent triggers and discussed in more detail below.
3.1.1 Food
The most common foods causing anaphylaxis varies by region, in North America 
the most common food allergies includes milk, egg, peanuts, tree nuts, fish, 
shellfish, wheat, soy, and sesame [24]. Allergenic proteins have been identified for 
these common causes as well as in rice, barley, buckwheat, mustard, celery, potato, 
carrots, and apples [25].
Most cases of anaphylaxis due to food occurs in children or those with known 
food allergies, and fatal cases are rare [7, 8, 10]. When fatal, the cause of death 
is more often due to respiratory arrest, although shock can occur as well. Arrest 
occurs later compared to medication or venom, typically occurring 25–35 min after 
exposure [26].
3.1.2 Venom
Stinging insects belonging to the order Hymenoptera produce venoms that can 
cause anaphylaxis. The important insects from this order include bees, vespids 
(wasps, yellow jackets, hornets) and stinging ants [27]. Vespid venom additionally 
activates complement in an IgE independent mechanism, which may potentiate 
anaphylaxis [28]. In addition to hymenoptera venom, bites from rattlesnakes [29], 
Figure 1. 
Mechanisms of mast cell degranulation. Abbreviations: RCM, radiocontrast media; TLR. Toll-like receptor; 
SCF, stem cell factor; FcεRI, high affinity IgE receptor; FcγR, IgG receptor; TCR, T-cell receptor; NMBA, 
neuromuscular blocking agent; PAF, platelet activating factor; MHC, major histocompatibility complex.
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hamsters [30], and ticks [31] have been implicated as causes of anaphylaxis. Fatal 
cases due stings are more often due to shock than respiratory distress, arrest typi-
cally occurs 10–15 min after exposure [26].
3.1.3 Medications
The most common medications causing anaphylaxis are beta-lactam anti-
biotics, NSAIDs, neuromuscular blocking agents, and chemotherapy [9, 32] . 
However, nearly any medication has the potential to cause anaphylaxis, some 
drugs that have been implicated includes intravenous iron [33], gelatin found in 
a vaccines [34], dextran [35], and human serum albumin [36]. In addition to IgE 
mediated mechanisms, other mechanisms of inducing anaphylaxis have been 
identified for multiple drugs [37]. This includes complement or contact activa-
tion (e.g. radiocontrast media, pegylated compounds, liposomal drugs [38], and 
heparin contaminated with oversulfated chondroitin sulfate (OSCS) [39]) and 
direct mast cell activation (e.g. opiates and neuromuscular blockers [37]). There 
have been multiple reports of anaphylaxis occurring to biologic agents, where the 
patient had IgG but no detectable IgE antibody to the therapy [40]. In medica-
tion induced anaphylaxis, shock is more common in severe cases than respiratory 
distress [26, 41]. Arrest occurs can occur rapidly after exposure, most cases in less 
than 5 min [26].
3.2 Biochemical mediators and clinical pharmacology
Once activated, mast cells and basophils release a cascade of mediators which 
cause physiologic changes, activate other immunology pathways, and attract other 
immune cells. Preformed mediators are released immediately upon activation 
including histamine, tryptase, heparin, and chymase. Over several minutes addi-
tional mediators are generated including platelet activating factor, leukotrienes, 
and prostaglandins (Table 2). Various cytokines and chemokines are generated over 
several hours further propagate the inflammatory response [37, 42].
Foods Milk
Eggs
Peanuts
Tree nuts
Fish
Shellfish
Soy
Wheat
Sesame
Bites/venoms Hymenoptera venom (bee, vespids*, ants)
Tick
Rattlesnake
Hamster
Medications Antibiotics
NSAIDs*
Chemotherapy
Neuromuscular blocker*
Radiocontrast*
Opioids*
*Non-IgE mediated mechanisms identified as alternative or additional mechanism.
Table 1. 
IgE-dependent triggers [9, 24, 27, 29–32].
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Histamine has long been considered the principal mediator of anaphylaxis, and 
concentrations of histamine correlate with symptom severity [42]. Histamine acts 
on receptors to cause vasodilation and increased permeability [43, 44], broncho-
constriction, and increase mucus secretion. In the heart H2 receptors have positive 
chronotropic and ionotropic effects and causes coronary vasodilation, while the H1 
receptor causes coronary vasoconstriction [45].
Platelet activating factor (PAF) has been increasingly recognized as important in 
the pathophysiology of anaphylaxis. In PAF receptor knockout mice, symptoms of 
anaphylaxis are reduced [46]. In humans PAF levels in the serum directly correlates 
with the severity of anaphylaxis symptoms [47]. In addition to activating platelets, 
PAF causes vasodilation, increased vascular permeability, decreased myocardial 
contractility, bronchoconstriction, and initiates allergic response through stimula-
tion of other mediators [48, 49].
4. Signs and Symptoms
Anaphylaxis causes a generalized systemic reaction affecting multiple organ 
systems, symptoms involving the skin occur in 80–90% of cases, respiratory tract 
in 70%, GI in 45%, CV in 45%, and CNS involvement in 15% [50, 51]. The cardio-
vascular and respiratory systems are the principal shock organs in fatal anaphylaxis. 
Death occurs in most often due to shock or acute respiratory distress, but DIC and 
epinephrine overdose have also been cited as cause of death [26, 52–55]. Most fatal 
cases of anaphylaxis due to medication or venoms are a result of shock, in food 
related anaphylaxis respiratory involvement is the main cause of death although 
shock is still possible [26, 56].
Anaphylaxis develops rapidly with symptoms developing in minutes. Biphasic 
reactions, where symptoms resolve and then reappear later occurs around 20% of 
the time [57]. A systematic review of biphasic reactions found the medium time 
between resolution of initial symptoms and onset of delayed symptoms to be 11 h, 
with a range of 0.2–72 h  [58].
4.1 Cardiovascular changes
Cardiovascular manifestations of anaphylaxis develop due to direct and indirect 
effects of mediators on the vasculature and heart. Increased vascular permeability 
causes rapid fluid extravasation, with up to 35% of plasma volume shift occurring 
Immediate 
release
Histamine Vasodilation, edema, bronchoconstriction, mucus secretion, 
change myocardial contractility
Tryptase Vasodilation, edema, bronchoconstriction
Chymase Vasodilation, edema, mucus secretion
Heparin Initiates formation of bradykinin causing edema
TNFa Bronchoconstriction
Rapid generation 
(min)
PAF Vasodilation, edema, bronchoconstriction, platelet activation, 
decrease myocardial contractility
LTs C4, D4 Potent vasoactive and spasmogenic agents
Prostaglandin D2 Bronchospasm and increase mucus secretion
Table 2. 
Physiologic effects of mediators [42, 49].
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in a matter of minutes [59, 60]. Vascular smooth muscle relaxation causes vasodila-
tion and a rapid decrease in SVR [61, 62]. Rapid drop in measured CVP suggests 
that venodilation plays a major as well. The combined effects as extravasation and 
venodilation cause significant reduction in preload. This can be severe enough to 
cause Empty ventricle syndrome, has been documented in autopsies of patients who 
died from anaphylaxis [63].
Arrhythmias and myocardial infarction can also be seen in anaphylaxis. 
Arrhythmias may develop due to the combined direct effect of mediators, and hemo-
dynamic changes previously described. Myocardial infarctions seen in anaphylaxis may 
be due to decreased venous return and direct effects of mediators on coronary arteries 
causing vasospasm or disruption of atherosclerotic plaques [64, 65].
Compensatory response to these changes includes rise in heart rate, ejection fraction, 
and cardiac index [61, 62]. Although Tachycardia is typical in anaphylaxis, although 
bradycardia may be seen as well. Bradycardia occurs due to a compensatory Bezold-Jarisch 
reflex, and has been found to have lower mortality rates when compared to cases of 
anaphylactic shock with tachycardia [66, 67]. Atropine therefore should not be adminis-
tered, as it would counteract this protective effect and may increase mortality [68].
4.2 Respiratory changes
The entire respiratory tract can be affected in anaphylaxis, involving the upper 
airway and/or lower airway [69]. Upper airway symptoms develop due to fluid 
extravasation causing mucosal edema [70]. Some symptoms of upper airway 
involvement include angioedema, stridor, dysphagia, and rhinorrhea [50, 71]. 
Lower airway obstruction occurs due to mucosal edema, bronchospasm, and 
mucous plugging [70]. Oxygen saturation may decrease secondary to respiratory 
effects of anaphylaxis limiting airflow. When there is diffuse lower respiratory tract 
involvement, decreased oxygen saturation can persist despite endotracheal intuba-
tion [72]. When PaO2 is adequate, tissue oxygenation can still be compromised 
causing anaerobic metabolism. In one study on rats, tissue oxygenation of muscle 
decreased faster in anaphylaxis compared to nicardipine induced hypotension. The 
anaphylactic group also showed a greater increase in lactate and lactate-pyruvate 
ratio indicating depletion of intracellular energy storage [73].
4.3 Mucocutaneous, gastrointestinal, and neurologic changes
Mucocutaneous symptoms (e.g. flushing, pruritus, angioedema, and urticaria) 
are common in anaphylaxis, however in cases of shock cutaneous symptoms are 
often absent. Vasodilation and increased vasculature permeability leads to flush-
ing and angioedema [74]. In addition to vascular changes, urticaria develops due 
inflammatory cell infiltration and neuropeptide release from sensory nerves [75]. 
Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal 
pain [76]. These symptoms are likely due to intestinal smooth muscle contraction 
and alterations in water and electrolyte absorption [77, 78]. Neurologic changes 
are mostly secondary to hypotension and decreased perfusion and may manifest as 
dizziness, confusion, syncope/presyncope, or headache [50]. More serious effects 
including seizure and stroke may also be seen but are rare [74, 79].
5. Diagnosing
It is often difficult to recognize anaphylaxis, and many cases go undiagnosed 
[80, 81]. Early intervention in acute anaphylaxis reduces risk of severe reaction and 
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need for hospitalization [82]. In order to aid in diagnosis of anaphylaxis, diagnostic 
criteria have been developed (Table 3). In the clinic or emergency department, it 
may be unclear if the patient had been exposed to an allergen. In the ICU or operating 
room, rapid development of symptoms after administering medication makes recog-
nizing anaphylaxis easier. Following the acute phase of anaphylaxis, serum tryptase 
and histamine should be measured to aid immunologist in confirming the diagnosis 
of anaphylaxis during follow-up care [83, 84]. Plasma tryptase remains elevated for 
6 h following the onset of symptoms, but histamine levels remain elevated for just 1 h 
[85, 86]. Urinary histamine metabolites remain elevated for a longer period and may 
therefore be more useful than plasma histamine for confirming anaphylaxis [86].
5.1 Diagnostic criteria
5.2 Differential diagnosis
There are several conditions which may mimic certain characteristics of anaphy-
laxis. Acute anxiety can present as dyspnea and near syncope with hyperventilation. 
Hypoglycemia can precipitate an altered sensorium and syncope. Vasovagal epi-
sodes can involve nausea with vomiting, hypotension, pallor, bradycardia, diapho-
resis and syncope. Additional considerations include severe reactive airway disease, 
vocal cord dysfunction and non-allergy mediated angioedema. Vasovagal episodes 
can involve nausea with vomiting, hypotension, pallor, bradycardia, diaphoresis 
and syncope [50, 88].
6. Management
There is a general lack of evidence basis for the treatment of anaphylaxis [89], 
but multiple expert guidelines highlight the chief treatment as epinephrine, oxygen, 
and fluids [86, 90, 91].
6.1 Principal treatment
Epinephrine is the first line treatment of anaphylaxis, and delayed administra-
tion increases the likelihood of poor outcomes [54, 55, 92]. Despite this, use of 
Anaphylaxis is likely when one of the following criteria is fulfilled:
1. Acute onset of an illness (minutes to several hours) with involvement of the skin and/or mucosal tissue 
and at least one:
a. Respiratory compromise
b. Reduced blood pressure or symptoms of end-organ damage
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient
a. Involvement of the skin-mucosal tissue
b. Respiratory compromise
c. Reduced blood pressure or associated symptoms
d. Persistent gastrointestinal symptoms
3. Reduced blood pressure after exposure to known allergen for that patient (minutes to several hours)
a. Adults: systolic blood pressure of less than 90 mm Hg or greater than 30% decrease from that person’s 
baseline
b. Infants and children: low systolic blood pressure (age-specific) or greater than 30% decrease in systolic 
blood pressure
Table 3. 
Clinical criteria for diagnosing anaphylaxis, modified from [3, 87].
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epinephrine in anaphylaxis is infrequent and often delayed [80]. There are no 
contraindications for use of epinephrine in anaphylaxis, and it should still be 
administered in patients with history of heart disease [93].
Epinephrine exerts its effects via alpha and beta adrenergic receptors in a dose-
dependent response where beta receptors effects are dominant at low doses, but 
alpha receptors effects are seen at higher doses. The α1 receptors cause vasoconstric-
tion increasing peripheral vascular resistance and blood pressure and improving 
coronary and cerebral perfusion. The β1 receptors exert positive chronotropic and 
inotropic effects which improves cardiac output and increases blood pressure. In the 
respiratory system, β2 receptors stimulation results in bronchodilation, and relief 
and respiratory symptoms. β receptors also inhibit release of mediators from mast 
cells and basophils, via increased cAMP production [94].
In most situations intramuscular administration is preferred, but IV epinephrine 
can be used in the ICU. IM epinephrine should be given in 0.2–0.5 mg doses (1:1000 
dilution), and repeated every 5 min depending on the resolution of symptoms [86]. 
Studies showed that peak epinephrine concentrations were higher when epineph-
rine was given IM into the thigh, compared to IM administration in the arm or 
subcutaneous administration [95]. Multiple doses of epinephrine may be required 
to reverse symptoms [96]. Care should be taken to closely monitor pulse and blood 
pressure when epinephrine is administered intravenously as there is greater risk of 
severe adverse effects compared to intramuscular administration including arrhyth-
mias and myocardial infarctions [97].
Following epinephrine administration, patients should continue to be assessed 
for worsening signs of anaphylaxis. Patients should be placed on pulse oximeter and 
given high flow oxygen as needed. Patients in anaphylactic shock should be placed 
in supine or Trendelenburg position to increase blood return to the heart. Patients 
who are sitting upright can have a significant decrease in preload leading to empty 
ventricle syndrome and PEA [98].
Due to the intravascular depletion, fluid is often necessary to maintain pres-
sure. Crystalloids or colloids may be used, although physicians should be aware of 
the anaphylactic potential of some colloid solutions. Normal saline (0.9% saline) 
should be chosen over other crystalloids as it remains in the intravascular space 
longer than dextrose solutions [86, 99]. Caution should taken while giving fluids to 
patients with heart failure to prevent fluid overload.
6.2 Adjunct treatments
Antihistamines are often given as adjunct therapy in anaphylaxis, however there 
is no evidence to support or advise against their use in anaphylaxis [100]. Steroids 
may be used to prevent biphasic anaphylaxis [86], although there is no evidence to 
support the use of steroids in acute treatment of anaphylaxis [101, 102].
Nebulized albuterol or other beta-2 agonists may be useful to treat respiratory 
distress due to bronchoconstriction. While there is no clinical trial on use of these 
medications in anaphylaxis, their effectiveness in treating other allergic diseases 
offers some basis for their use [90].
6.3 Additional consideration
Beta blockers may complicate the treatment of anaphylaxis, as some of the 
beneficial effects of epinephrine will be diminished [103]. In patients on beta-
blockers who do not respond to epinephrine and fluids, other vasopressors should 
be considered. Glucagon has been reported to be a successful treatment in several 
case reports of patients on beta blockers who experienced anaphylactic shock [104]. 
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Glucagon mechanism of action is via direct activation of adenylate cyclase, bypass-
ing the blocked adrenergic receptors.
Vasopressin or phenylephrine can be used to increase systemic vascular resis-
tance without further increasing heart rate. Dopamine or norepinephrine can be 
added in cases of relative bradycardia [105]. Mechanical support with ECMO has 
been reported to be successful at treating refractory anaphylaxis with profound 
myocardial dysfunction [106].
Methylene blue has been reported to be an effective treatment in cases of severe 
anaphylaxis not responding to epinephrine [88], as well as cases of anaphylaxis 
without hypotension. Methylene blue inhibits NO mediated vasodilation via 
competitive inhibition of guanylate cyclase decreasing cyclic GMP production and 
subsequent vasodilation [107]. This mechanism acts independent of adrenergic 
receptors, and may be effective in patients with refractory anaphylactic shock [108].
6.4 Follow up
Before discharging a patient that experienced anaphylaxis, they should be 
referred to an immunologist for a thorough evaluation. Labs to assess for ana-
phylaxis (i.e. tryptase, histamine) should be drawn to assist allergist in making a 
diagnosis. Patients should also receive a prescription for an epinephrine autoinjec-
tor, along with education on how to use it [87].
7. Conclusions
Anaphylaxis is a rapidly acting life-threatening hypersensitivity reaction. 
Diagnosis of anaphylaxis can be difficult, and early recognition and treatment is 
essential to prevent development of shock. Shock is more common in cases due to 
medication compared to food, although shock can occur. The primary treatment 
in anaphylactic shock is epinephrine, fluids, and oxygen. Additional medications 
including antihistamines, steroids, and inhaled beta-agonist should be used as 
needed. In patients who do not respond to epinephrine, other vasopressors or 
mechanical support can be used.
Abbreviations
AAAAI American Academy of Allergy, Asthma and Immunology
ACAAI American College of Allergy, Asthma and Immunology
EAACI European Academy of Allergy and Clinical Immunology
WAO World Allergy Organization
Ig immunoglobulin
Antigen molecule capable of interacting with Ig, includes immunogens and 
haptens
Immunogen molecule that can interact with Ig and cause an immune response
Hapten molecule that can interact with Ig, but cannot cause immune 
response on its own
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